Biomarkers of erlotinib response in non-small cell lung cancer tumors that do not harbor the more common epidermal growth factor receptor mutations

Non-small cell lung cancer (NSCLC) represents approximately 85% of all lung cancers, which are the leading cause of cancer-related deaths in the world. Tyrosine kinase inhibitors such as erlotinib represent one therapeutic options presently recommended for tumors produced by activating mutations in...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Int J Clin Exp Pathol
Main Authors: López-Ayllón, Blanca D, de Castro-Carpeño, Javier, Rodriguez, Carlos, Pernía, Olga, de Cáceres, Inmaculada Ibañez, Belda-Iniesta, Cristobal, Perona, Rosario, Sastre, Leandro
Formato: Artigo
Idioma:Inglês
Publicado em: e-Century Publishing Corporation 2015
Assuntos:
Original Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4440106/
https://ncbi.nlm.nih.gov/pubmed/26045797
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados